Saudi experts’ recommendation for RSV prophylaxis in the era of COVID-19
| Autor: | Mohamed Y. Alhindi, Adel S. Alharbi, Mohamed Alzahrani, Saleh Alharbi, Abdulrahman N. Alodayani, Abdulrahman Alnemri |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Palivizumab
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) business.industry viruses Public health General Medicine Disease 030204 cardiovascular system & hematology medicine.disease 03 medical and health sciences 0302 clinical medicine Bronchiolitis Viral pneumonia Family medicine Health care Medicine 030212 general & internal medicine business Socioeconomic status medicine.drug |
| Zdroj: | Saudi Medical Journal. 42:355-362 |
| ISSN: | 1658-3175 0379-5284 |
| DOI: | 10.15537/smj.2021.42.4.20200769 |
| Popis: | Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and viral pneumonia in pediatrics worldwide. In the Kingdom of Saudi Arabia (KSA), the prevalence of RSV is 23.5% in pediatric patients with acute lower respiratory tract illness. Coronavirus disease (COVID-19) poses critical public health and socioeconomic challenges in KSA. The Saudi Pediatric Pulmonology Association (SPPA), a subsidiary of the Saudi Thoracic Society (STS), developed a task force to determine the potential challenges and barriers to the RSV immunoprophylaxis program during the era of COVID-19 and to compose a practical, nationwide, and multidisciplinary approach to address these challenges. Some of the recommendations to manage these challenges include increasing the number of RSV immunoprophylaxis clinics, drive-thru visits, home-care services, and swift referrals to the RSV immunoprophylaxis program specialists. Additional training is required for healthcare personnel to add RSV immunoprophylaxis to the regular immunization schedule. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|